Switching From Ceftriaxone to Cefotaxime Significantly Contributes to Reducing the Burden of Clostridioides difficile infections | Zendy

Sebastian Wendt | Zendy; Donald Ranft | Zendy; Arne C. Rodloff | Zendy; Norman Lippmann | Zendy; Christoph Lübbert | Zendy

Open Access

Switching From Ceftriaxone to Cefotaxime Significantly Contributes to Reducing the Burden of Clostridioides difficile infections

Author(s) -

Sebastian Wendt,

Donald Ranft,

Arne C. Rodloff,

Norman Lippmann,

Christoph Lübbert

Publication year - 2020

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofaa312

Subject(s) - medicine , clostridioides , ceftriaxone , cefotaxime , fidaxomicin , c difficile , clostridium difficile , antibiotics , intensive care medicine , microbiology and biotechnology , vancomycin , bacteria , biology , genetics , staphylococcus aureus

We analyzed Clostridioides difficile infection (CDI) rates and various antimicrobials’ application densities from 2013 to 2019 at Leipzig University Hospital, Germany, by using multivariate linear regression. Ceftriaxone application was the only independent predictor of CDI incidence. Thus, antibiotics’ specific pharmacokinetic and pharmacodynamic properties such as biliary excretion of ceftriaxone in its active form should be considered when determining their potential to cause CDI.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research